Last reviewed · How we verify
Mencevax™ ACW
Mencevax ACW is a meningococcal polysaccharide conjugate vaccine that stimulates immune response against Neisseria meningitidis serogroups A, C, W, and Y.
Mencevax ACW is a meningococcal polysaccharide conjugate vaccine that stimulates immune response against Neisseria meningitidis serogroups A, C, W, and Y. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.
At a glance
| Generic name | Mencevax™ ACW |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Meningococcal conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains purified polysaccharide capsules from meningococcal serogroups A, C, W, and Y conjugated to a protein carrier, which enhances immunogenicity and T-cell dependent immune response. This conjugation approach improves antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against invasive meningococcal disease caused by these serogroups.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Headache
- Myalgia
- Fatigue
Key clinical trials
- Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |